October 2, 2025 - Hope to see you at Awards tonight! | | |
This week:
- Kardium’s Technology Used Commercially for the First Time
- Eupraxia Announces Positive Clinical Data Following US$80M Public Offering
- Need Extra Hands in the Lab? Hire CASTL Bioscience Trainees at No Cost!
- Redwood AI Shares Reasons to Attend Invest in BC
- Deadline Extended to Oct 5 to Meet with J&J
| | |
Kardium’s Technology Used Commercially for the First Time
Following recent FDA approval of its Globe Pulsed Field System, Kardium has now seen the first commercial use of its revolutionary technology. Successful procedures using the integrated mapping and ablation system were performed in the U.S. by Dr. Devi Nair, Chief of Cardiac Electrophysiology and EP Research at St. Bernards Medical Center in Jonesboro, Arkansas. Read more.
| | |
Eupraxia Announces Positive Clinical Data Following US$80M Public Offering
Building on last week’s US$80 million public offering, Eupraxia reports encouraging results from its latest clinical readout. Patients receiving the highest planned dose in the ongoing Phase 2b study showed positive outcomes, reinforcing the promise of its therapeutic programs. Read more.
| | |
Need Extra Hands in the Lab? Hire CASTL Bioscience Trainees at No Cost!
Employers can benefit from motivated BC youth trained through the CASTL Elevate BC program. Trainees gain six weeks of hands-on training in lab techniques, bioprocessing, and quality compliance and then are available for free, four-week placements starting mid-October. Enhance your team while supporting workforce development. Contact Mauricio Romero at mauricio@castlcanada.ca to register or schedule interviews.
| | | | |
Redwood AI Shares Reasons to Attend Invest in BC
Invest in BC offers unparalleled opportunity for local companies to gain international exposure. We are now 80% sold out of tickets, so secure yours, today.
Redwood AI’s CEO, Louis Dron, reflects on last year’s event:
“Invest in BC was one of the best events we attended all year. The connections made led to collaborations with local biotech companies and partnerships with federal officials supporting us with grants and opportunities. Exposure to diverse investment professionals helped refine our business narrative. We wholeheartedly recommend this event for any company seeking to establish meaningful, sometimes hard-to-reach partnerships.”
| | |
Deadline Extended for Applications to Meet with Johnson & Johnson
The application deadline to meet with Johnson & Johnson has been extended to October 5, 2025. Interested innovators are encouraged to apply before the new deadline to secure a chance for a 1:1 meeting with the J&J Innovation Global Partnering Team. Apply here.
| | |
Providence Health Care Ventures partners with ViewsML to accelerate cancer research using AI-driven virtual staining technology that identifies disease markers without traditional wet lab tests. Read more.
| | | | |
adMare BioInnovations’ upcoming Vancouver Innovation Centre, in Mount Pleasant is launching Q1 2026. The building offers flexible lab and office spaces designed to support the next generation of small to mid-sized life science companies workin on advanced research and innovation projects. Read more.
| | |
Reciprocal tariff relief for EU pharmaceuticals takes effect September 1, 2025, exempting certain unpatented pharmaceutical products from the 15% reciprocal tariff under U.S. Harmonized Tariff Schedule rules. Read more.
The Government of Canada is investing over $13 million to improve access to sexual and reproductive health services, supporting community organizations, awareness campaigns, and travel assistance for safe, inclusive care. Read more.
| | |
Congratulations to Oliver Technow for receiving the 2025 Bloom Burton award. Kudos also goes to BC’s Ali Tehrani, recognized as a finalist for outstanding leadership in Canada’s life sciences sector. Read more.
Congrats to Eva Fong, CFO of WELL Health Technologies, and Kathryn Hayashi, former CEO of TRIUMF Innovations, who are among six executives honored at Business in Vancouver’s 2025 C-Suite Awards this November. Read more.
| | BC small- and medium-sized businesses can access funding through PacifiCan’s Regional Tariff Response Initiative (RTRI) to boost productivity, diversify exports, and strengthen supply chains. Learn more | | See our expanded list of current life sciences opportunities on our website. | | |
| Thrive Health is a digital health platform company, founded in 2016 with a mission to make healthcare work better for everyone. The company provides an interactive patient engagement platform that allows healthcare providers to build custom clinical workflows, and offers patients enhanced access to their health data. Learn more | | |
Nasim Gholamshahbazi - CEO & Co-founder at NTP R&D Services Ltd. Specializing in electro spun nanofiber technology for skincare, wellness, advanced filtration, and life sciences. With expertise in electrospinning and biopolymer innovation, we support applications in cell culture, tissue engineering, and drug delivery, bridging science and industry to deliver innovative, sustainable solutions in health, beauty, and biotech. Learn more
| | |
Until next week!
LSBC Team
| | |
October 7 - Join us for Blakes Breakfast Speaking Series: Resilience: Current Uncertainty, and Forward Planning
This session brings together BC’s life sciences community for insight, strategy, and connection. The Blakes Breakfast Speaking Series will feature experts discussing market trends, resilience, and forward planning, with opportunities to engage both in person over breakfast and online via live chat.
|
| |
October 28 - 29 - Join us for our 10th Annual Invest in BC presented by Lumira Ventures
Life Sciences BC is pleased to announce the 10th annual Invest in BC presented by Lumira Ventures. This highly anticipated event serves as a premier gathering for life sciences innovators in British Columbia, connecting them with investors and potential partners locally, nationally, and around the world.
| | |
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson’s Disease
AbbVie has submitted a New Drug Application to the FDA for tavapadon, a once-daily oral therapy for Parkinson’s disease, supported by Phase 3 TEMPO trial data. If approved, it could provide a new option to manage symptoms and motor fluctuations... Read more
| | |
| |
New Data on Hologic’s AI-Powered Mammography Technology to Be Presented at EUSOBI
Hologic will share new EUSOBI data showing its Genius AI® Detection mammography technology performs comparably to expert radiologists in assessing tumor aggressiveness... Read more
| | |
| |
Vancouver Partnership Uses AI-Driven Virtual Biomarker Staining to Accelerate Cancer Research and Digital Pathology
Providence Health Care Ventures and ViewsML are partnering in Vancouver to apply AI-driven virtual biomarker staining, enabling faster tissue analysis, improved sample use, and accelerated cancer research...Read more
| | |
| |
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
AbbVie is building a $195M API facility in North Chicago to increase U.S. production of medicines for immunology, oncology, and neuroscience, expected to be operational by 2027... Read more
| | |
| |
U.S. FDA Approves TREMFYA® (guselkumab) for the Treatment of Pediatric Plaque Psoriasis and Active Psoriatic Arthritis, Marking a First and Only Approval for an IL-23 Inhibitor
The FDA has approved TREMFYA® (guselkumab) for treating pediatric plaque psoriasis and active psoriatic arthritis, marking the first IL-23 inhibitor approved for children... Read more
| | |
| |
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Eupraxia’s EP-104GI demonstrated positive outcomes in the RESOLVE trial for eosinophilic esophagitis, showing notable improvements without serious adverse effects... Read more
| | |
AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) – an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
AbbVie has filed a BLA with the FDA for Pivekimab sunirine (PVEK), an experimental treatment for the rare blood cancer BPDCN, aiming to provide a new therapy option... Read more
| | |
COPA-DATA and Cytiva Tackle Connectivity Issues Together
COPA-DATA and Cytiva are collaborating to add MTP technology to the UNICORN platform, enhancing connectivity, automation, and efficiency in biopharmaceutical operations... Read more
| | |
Kardium Announces First Commercial Procedures with the Globe® Pulsed Field System, the World’s Most Advanced Solution for Atrial Fibrillation
Kardium completed its first commercial procedures using the Globe® Pulsed Field System for atrial fibrillation, showing strong safety and effectiveness, with plans to expand use across the US... Read more
| | |
ME Therapeutics Secures U.S. Patent For Lead Candidate And Advances Broader Therapeutic Programs
ME Therapeutics has obtained a U.S. patent for its lead G-CSF antibody, H1B11-12, while progressing its pipeline of cancer therapies aimed at boosting immune response and targeting tumor suppression... Read more
| | |
Labcorp Announces Collaboration with Roche to Advance Digital Pathology Capabilities
Labcorp is working with Roche to implement FDA-cleared digital slide scanners, improving pathology diagnostics and supporting remote analysis and AI use... Read more
| | |
Reciprocal Tariff Relief For EU Pharmaceuticals
The U.S. has exempted certain unpatented EU pharmaceuticals from the 15% reciprocal tariff, effective retroactively from September 1, 2025, providing importers relief if proper classification and documentation are maintained... Read more
| | |
| |
Manager, Memberships & Sponsorships
This role will manage the portfolio of the members and sponsors. With responsibility for securing agreements, the Manager, Memberships and Sponsorships leads acquisition and retention strategies and the research of members’ and sponsors’ needs and opportunities...Learn more.
| | |
| |
Scientist - Structural Biology
This position supports comprehensive molecular insights and structure-based design for drug-target assessment, mechanism of action, protein-protein and protein-ligand interactions, as well as protein engineering to facilitate drug discovery across various therapeutic areas...Learn more.
| | |
| |
Research Assistant, In Vivo Pharmacology
Seeking an experienced research assistant to work in the Preclinical Group, reporting to the Senior Research Scientist, Preclinical. The research assistant will be responsible for conducting and supporting in vivo/in vitro studies to characterize the pharmacodynamics, pharmacokinetics/distribution...Learn more.
| |
Administrative Assistant (Intermediate)
This role requires a resourceful and organized individual who can manage multiple priorities, maintain confidentiality, and support cross-functional teams to ensure smooth and efficient office operations...Learn more
| | |
Scientist – CADD Data & Tools
HTuO Biosciences is hiring a Computational Scientist to develop CADD tools and data pipelines. The role requires Python expertise, knowledge of quantum chemistry, molecular dynamics, and CADD methods... Learn more
| | |
Senior Software Engineer
This role requires developing high-performance scientific software, focusing on delivering high-quality, accurate code in a high-performance computing environment. Your work will be crucial in projects where the correctness of software output is paramount... Learn more
| | |
| Post a Job on the LSBC Website | |
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings can be reposted on BioTalent Canada's The Petri Dish. Want more info? Contact membership@lifesciencesbc.ca
| | If you haven't already, sign-up for this and our weekly events newsletter | | Follow LSBC on Social Media | | | | |
